Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- AXSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Axsome Therapeutics, Mental Health America partner for Mental Health Month
- Axsome Therapeutics price target raised to $193 from $190 at RBC Capital
- Positive Outlook on Axsome Therapeutics Driven by Auvelity’s Strong Commercial Performance
- Positive Outlook on Axsome Therapeutics’ AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue